Arch Venture Fund Xiii, L.P.
At a glance: Arch Venture Fund Xiii, L.P. is 10% Owner at Lyell Immunopharma (LYEL). Their latest SEC Form 4, filed Nov 5, 2026, reported a purchase of $25.0M. On file: 1 purchase line ($25.0M) and 0 sale lines ($0).
Disclosed holdings: about $53.6M of LYEL stock: 3,747,790 shares (including shares held indirectly, e.g. through a trust or fund) reported on its latest Form 4 (filed Nov 5, 2026), valued at the Nov 13, 2026 close of $14.30. This counts only LYEL shares reported to the SEC; it leaves out cash, other investments, options and unvested awards, so it is not total net worth.
10% Owner at Lyell Immunopharma, Inc. (LYEL)
Purchase track record
Not enough history. Based on 0 purchases with a full 90 days of price history.
Reported trades
| Filed | Stock | Type | Shares | Price | Value | Since |
|---|---|---|---|---|---|---|
| Nov 5SEC | LYELLyell Immunopharma, Inc.First buyStake +163%Before earnings | Buy | 2,321,2623,747,790 held (+163%) | $10.77 | $25.0M | +32.8% |
- Buy
10% Owner Arch Venture Fund Xiii, L.P. bought $25.0M of LYEL at $10.77 — first open-market purchase in our records; raises the stake by 163%.
Follow Arch Venture Fund Xiii, L.P.
Get one email when Arch Venture Fund Xiii, L.P. files a new purchase or sale. Free.
At most one email a day about Arch Venture Fund Xiii, L.P., plus the free Monday email. Already subscribed? Use the same email to add them. Unsubscribe anytime. Facts from public filings, not advice.